Skip to main content
The $89 Billion Pot-Stock Alternative
Investors are ditching dicey pot stocks and flocking to one fully-legalized market that’s primed for massive moves by 2026. The one company that could capitalize on this momentum.
Discover What Could Be 2021’s #1 Cannabis Stock

BHC Insider Trading (Bausch Health Companies)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$120,958.71

Bausch Health Companies Insider Trading History Chart

Bausch Health Companies Share Price & Price History

▼ -0.64 (-1.86%)
As of 05/6/2021 01:00 AM ET
Days: 30 | 90 | 365
Massive land holdings yield chance for next gold discovery
Right next door to Kirkland Lake´s famous Fosterville Mine, read what geologist Byron King thinks about this exciting new gold opportunity
Find out which stock we´re talking about

Bausch Health Companies Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/8/2020William Douglas HumphriesSenior OfficerSell5,667C$21.34C$120,958.71190,912
9/13/2019Joseph PapaDirectorBuy30,000C$30.77C$923,076.00473,284
8/16/2019William Douglas HumphriesSenior OfficerBuy30,703C$27.95C$858,187.6689,220
8/12/2019Christina AckermannSenior OfficerSell3,418C$29.63C$101,277.737,385
7/11/2019Christina AckermannSenior OfficerSell3,968C$32.75C$129,948.833,967
See Full Table
Bausch Health Companies logo
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Read More on Bausch Health Companies

Today's Range

Now: C$33.78

50 Day Range

MA: C$38.73

52 Week Range

Now: C$33.78


851,530 shs

Average Volume

670,803 shs

Market Capitalization

C$12.11 billion

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Bausch Health Companies?

Bausch Health Companies' top insider shareholders include:
  1. Joseph Papa (Director)
  2. William Douglas Humphries (Senior Officer)
  3. Christina Ackermann (Senior Officer)
#1 Stock With Upside Potential
Undervalued stock aims to separate itself in hot market after targeting rare diseases
Click to get your free report